MedTrace Logo

Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery

NCT01826279 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-01-30

No results posted yet for this study

Summary

The purpose of this study is to investigate potential metabolic effects of resveratrol in morbidly obese women undergoing gastric bypass surgery.

The investigators hypothesize that resveratrol will:

* Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion
* Decrease hepatic and adipose tissue VLDL-TG uptake
* Increase insulin sensitivity

The investigators will look at changes in:

* Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry)
* VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous abdominal adipose tissue, visceral adipose tissue and liver tissue)
* Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)
* Regulation of liver fat handling
* Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)

Conditions

Interventions

DIETARY_SUPPLEMENT

Resveratrol

500mg 3 times daily for 1 month

OTHER

Placebo

1 placebo tablet 3 times daily for 1 month

Sponsors & Collaborators

  • The Ministry of Science, Technology and Innovation, Denmark

    collaborator OTHER_GOV

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Søren Nielsen, MD, associate professor, DMSc · Department of Endocrinology and Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01826279 on ClinicalTrials.gov